Shane Lloyd
Biographic Data
| ID | 7700097 |
|---|---|
| NAME | Shane Lloyd |
| GIVEN NAMES | Shane |
| FAMILY NAME | Lloyd |
| SIGNATURE | LLOYD S |
| AFFILIATIONS | University of Utah |
| ORCID | 0000-0002-4235-7652 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2012 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Risks of adverse health outcomes among older rural prostate cancer survivors in the Seer‐Medicare data
BACKGROUND: Rural prostate cancer patients face challenges such as greater distance for cancer treatment and care fragmentation. There have been very few studies investigating adverse health outcomes among prostate cancer survivors residing in rural areas. A comprehensive evaluation of adverse health outcomes among rural prostate cancer patients is needed to understand potential health disparities and provide scientific evidence for interventions…
Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436
HIV Risk among Men Who Have Sex With Men Who Have Experienced Childhood Sexual Abuse
No prominent works on this page.
HIV Risk among Men Who Have Sex With Men Who Have Experienced Childhood Sexual Abuse
Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436
Risks of adverse health outcomes among older rural prostate cancer survivors in the Seer‐Medicare data
BACKGROUND: Rural prostate cancer patients face challenges such as greater distance for cancer treatment and care fragmentation. There have been very few studies investigating adverse health outcomes among prostate cancer survivors residing in rural areas. A comprehensive evaluation of adverse health outcomes among rural prostate cancer patients is needed to understand potential health disparities and provide scientific evidence for interventions…
Cancer (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Oncology (2 works) · Cancer survivorship and care (1 work) · Cetuximab (1 work) · Chemotherapy (1 work) · Cisplatin (1 work) · Clinical trial (1 work) · Colorectal cancer (1 work)